SSY Group (HKG:2005) obtained drug production and registration approvals for four products from China's National Medical Products Administration as they pass the regulator's consistency evaluation.
The approvals are for Hemofiltration Replacement Fluid of Sodium Citrate used as replacement fluid in continuous renal replacement therapy and Benidipine Hydrochloride Tablets for the treatment of primary hypertension and angina pectoris.
The other two products comprise Polyvinyl Alcohol Eye Drops as a lubricant for dry eyes and a Fat Emulsion, Amino Acids and Glucose Injection for adult patients.